<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03560804</url>
  </required_header>
  <id_info>
    <org_study_id>100</org_study_id>
    <nct_id>NCT03560804</nct_id>
  </id_info>
  <brief_title>Use of Impedance Cardiography and Applanation Tonometry for Prediction of the Antihypertensive Effect of Two Drugs</brief_title>
  <official_title>Use of Impedance Cardiography and Applanation Tonometry for Prediction of the Antihypertensive Effect. Comparison Between an ATII Receptor Antagonist and a Diuretic.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AHEPA University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AHEPA University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal aim of the study is to determine whether the hemodynamic parameters measured
      with the two methods -impedance cardiography and applanation tonometry- can be predictive of
      the antihypertensive effect of two different classes of drugs, ATII antagonists and
      diuretics.

      The drugs that will be used in the study are olmesartan and chlorthalidone and the duration
      of the study is 12 months.

      The other basic aim of the study is to determine whether there is a difference (&gt;6mmHg)
      between the two drugs regarding the reduction of the mean 24hour blood pressure and the
      effect of them on the hemodynamic parameters.

      The hemodynamic parameters that will be measured by applanation tonometry are augmentation
      index, central blood pressure and pulse wave velocity.

      The hemodynamic parameters that will be measured by impedance cardiography are cardiac index,
      thoracic fluid content index, systemic vascular resistance index and others.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The principal aim of the study is to determine whether the hemodynamic parameters measured
      with the two methods -impedance cardiography and applanation tonometry- can be predictive of
      the antihypertensive effect of two different classes of drugs, ATII antagonists and
      diuretics.

      The drugs that will be used in the study are olmesartan and chlorthalidone and the duration
      of the study is 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 10, 2014</start_date>
  <completion_date type="Actual">September 15, 2017</completion_date>
  <primary_completion_date type="Actual">September 15, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulse wave velocity</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measured by Sphygmocor devive</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systemic vascular resistance</measure>
    <time_frame>12 months</time_frame>
    <description>Measured by impendance cardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulatory blood pressure</measure>
    <time_frame>12 months</time_frame>
    <description>Daytime and nighttime systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Arterial Stiffness</condition>
  <condition>Ambulatory Blood Pressure Monitoring</condition>
  <arm_group>
    <arm_group_label>Olmesartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ARB administration (OLMESARTAN) at a starting dose and titrating at 15 weeks according to reach blood pressure target</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chlorthalidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diuretic administration (chlorthalidone) at a starting dose and titrating at 15 weeks according to reach blood pressure target</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan</intervention_name>
    <description>Administration of olmesartan at starting dose and titrating in order to reach the target blood pressure.</description>
    <arm_group_label>Olmesartan</arm_group_label>
    <other_name>Olartan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorthalidone</intervention_name>
    <description>Administration of chlorthalidone at starting dose and titrating in order to reach the target blood pressure.</description>
    <arm_group_label>Chlorthalidone</arm_group_label>
    <other_name>Hygroton</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Drug naive patients with 1st or 2nd grade Arterial Hypertension according to the
             ESH/ESC guidelines 2013

          -  The patient has signed the concent form

        Exclusion Criteria:

          -  Secondary Hypertension

          -  3rd grade of Arterial Hypertension

          -  Chronic renal failure

          -  Diabetes Mellitus

          -  Sleep apnea syndrome

          -  Chronic or acute inflammatory diseases

          -  Stroke, myocardial infarction, angina pectoris in the past 6 months

          -  Heart failure

          -  Liver disease

          -  Neoplasms

          -  Pregnancy

          -  Valvular Heart disease

          -  Heigt &lt; 120cm or &gt; 230cm, Weight &lt;30kg or &gt;155kg

          -  Heart Arrhytmias

          -  Artificial cardiac pacemaker

          -  Hemodymanic unstable patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zebekakis Pantelis, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hypertension Excellence Center, 1st Department of Internal Medicine, AHEPA University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hypertension Excellence Center, AHEPA University Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54635</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>January 15, 2015</study_first_submitted>
  <study_first_submitted_qc>June 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2018</study_first_posted>
  <last_update_submitted>June 15, 2018</last_update_submitted>
  <last_update_submitted_qc>June 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AHEPA University Hospital</investigator_affiliation>
    <investigator_full_name>Maria Pikilidou, MD, MSc, PhD</investigator_full_name>
    <investigator_title>Post-doctoral researcher</investigator_title>
  </responsible_party>
  <keyword>olmesartan</keyword>
  <keyword>chlorthalidone</keyword>
  <keyword>hemodynamics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Chlorthalidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

